n (%) | |
---|---|
Age at diagnosis (years), Median; range | 63.8; 44.1–82.7 |
Female gender | 84 (79.2) |
Active smoking | 32 (30.2) |
Charlson comorbidity index ≥ 1 | 44 (41.5) |
Sarcopenia | 41 (38.7) |
Immunosuppressive disordersa | 12 (11.3) |
HIV | 1 (0.9) |
Pretreatment hemoglobin (g/L), Median; range | 129; 77–163 |
Pretreatment leukocyte count (109/L), Median; range | 7.6; 3.8–33.7 |
T stageb | |
1 | 3 (2.8) |
2 | 46 (43.4) |
3 | 27 (25.5) |
4 | 30 (28.3) |
Primary tumor size (cm), Median; range | 5.0; 1.0–15.0 |
Lymph node metastasisb | 67 (63.2) |
Radiation technique | |
IMRT | 9 (8.5) |
Tomotherapy | 20 (18.9) |
VMAT | 77 (72.6) |
Radiation dose (Gy) | |
Primary tumor, Mean; SD | 59.5; 1.2 |
Lymph node metastasis, Mean; SD | 57.9; 4.4 |
Elective, Mean; SD | 45.1; 4.0 |
Radiation treatment time (days), Mean; SD | 43.1; 4.6 |
Included in elective CTVc | |
Inguinal | 104 (98.1) |
Internal iliac | 106 (100.0) |
External iliac | 104 (98.1) |
Presacral | 106 (100.0) |
Mesorectal | 106 (100.0) |
Ischiorectal fossa | 101 (95.3) |
Low cranial borderd of elective CTV | 8 (7.5) |
Chemotherapy: all patients scheduled for FUMI × 2 | |
Omission of second cycle | 14 (13.2) |
Dose reduction of second cycle | 15 (14.2) |
Omission or dose reduction of second cycle | 29 (27.4) |
Second cycle platinum-based (cardiac toxicity) | 4 (3.8) |
White blood cell toxicity (CTCAE version 5.0) | |
G0 | 15 (14.2) |
G1 | 7 (6.6) |
G2 | 30 (28.3) |
G3 | 36 (34.0) |
G4 | 18 (17.0) |
Febrile neutropenia | 22 (20.8) |